Cardioxane

SKU: orb1300743

Description

Cardioxane (ADR-529) is a cardioprotective agent used in research to mitigate the cardiac toxicity associated with chemotherapeutic drugs like doxorubicin. Its applications span in vitro cell studies and in vivo animal models within oncology and cardiology research fields.

Research Area

Molecular Biology

Key Properties

• CAS Number: 149003-01-0
• MW: 304.73
• Purity: 99.80% (May vary between batches)
• Formula: C₁₁H₁₆N₄O₄·HCl
• SMILES: Cl.CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
• Target: Others,Topoisomerase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.5 mg/mL (8.2 mM);H2O:55 mg/mL (180.49 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:50 mg/mL (164.08 mM)

Bioactivity

• In Vivo:
  Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin reduces the tissue lesions in B6D2F1 mice (expressed as area under the curve of wound size times duration) by 96%, 70%, and 87%, respectively. Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin results in a statistically significant reduction in the fraction of mice with wounds as well as the duration of wounds.
• In Vitro:
  Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes. Dexrazoxane presumably exerts its cardioprotective effects by either binding free or loosely bound iron, or iron complexed to doxorubicin, thus preventing or reducing site-specific oxygen radical production that damages cellular components. Dexrazoxane specifically abolishes the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Dexrazoxane also induces rapid degradation of Top2beta, which paralleles the reduction of doxorubicin-induced DNA damage. Dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. Dexrazoxane is hydrolyzed to its active form intracellularly and binds iron to prevent the formation of superhydroxide radicals, thus preventing mitochondrial destruction.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ADR 529, ADR 529 Hydrochloride, ADR529, ADR-529, ADR529 Hydrochloride, ADR-529 Hydrochloride, Cardioxane, Cardioxane Hydrochloride, Cardioxane hydrochloride, Dexrazoxane, Dexrazoxane HCl, Dexrazoxane hydrochloride, inhibit, Inhibitor, NSC 169780, NSC169780, NSC-169780, ICRF 187, ICRF 187 Hydrochloride, ICRF187, ICRF-187, ICRF187 Hydrochloride, ICRF-187 hydrochloride, ICRF-187 Hydrochloride, Topoisomerase

Compound Identifiers

PubChem CID

11652428